KPC Pharmaceuticals, Inc. (600422.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 8.16

From 52W high−42.57%

Volume2.92M

Market capCNY 6.29B

P/E (TTM)18.0x

P/S (TTM)1.1x

Div yield2.21%

Key dataSep 18, 2026

Open

CNY 8.16

From 52W high

−42.57%

Volume

2.92M

Market cap

CNY 6.29B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

14.0x

P/E (TTM)

18.0x

RSI (14)

38.3

MomentumView details →

1D Return

−2.69%

YTD Return

−35.19%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

18.0x

EV/EBITDA

14.0x

EV/Sales

1.5x

P/S (TTM)

1.1x

P/B (TTM)

1.3x

ProfitabilityView details →

Gross Margin

36.67%

Net Margin

2.03%

EBITDA Margin

10.74%

ROE (TTM)

2.25%

ROA (TTM)

1.05%

Asset Turnover

0.50x

GrowthView details →

Revenue YoY

−28.21%

EPS YoY

−81.11%

FCF YoY

—

Revenue CAGR 3Y

−7.40%

EPS CAGR 3Y

−3.38%

EBITDA YoY

—

MomentumView details →

1D Return

−2.69%

YTD Return

−35.19%

1Y Return

−42.31%

RSI (14)

38.3

vs 50D SMA

−6.78%

vs 200D SMA

−22.08%

Capital & dividendView details →

Debt/Equity

0.29x

Current Ratio

2.09x

Quick Ratio

1.64x

Div Yield

2.21%

Div Rate

CNY 0.18

Div Growth 1Y

−40.00%

EarningsView details →

EPS (Actual)

−CNY 0.29

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

0.00%

Financials snapshotView financials →

Revenue (TTM)

5.80B

Net Income (TTM)

117.67M

Op. CF (TTM)

−185.01M

Next earningsOct 26, 2026 →

Latest newsMore news →

Kunming Pharma Group received regulatory acceptance to register medium-term notes of up to 1 billion yuan, valid for two years, with phased issuance allowed.19d ago

Kunming Pharma Group reported first-half 2026 revenue of 1.643 billion yuan, down 50.97% year-on-year, and a net loss attributable to shareholders of 364 million yuan, down 283.48% year-on-year.30d ago

Similar companies

辰欣药业603367.SH China Traditional Chinese Medicine Holdings Co. Limited00570.HK China Shineway Pharmaceutical Group Limited02877.HK CanSino Biologics Inc.06185.HK Lantheus Holdings, Inc.LNTH 亚虹医药-U688176.SH Find similar companies →

Latest newsMore news →

Kunming Pharma Group received regulatory acceptance to register medium-term notes of up to 1 billion yuan, valid for two years, with phased issuance allowed.19d ago Kunming Pharma Group reported first-half 2026 revenue of 1.643 billion yuan, down 50.97% year-on-year, and a net loss attributable to shareholders of 364 million yuan, down 283.48% year-on-year.30d ago